In silico design: Extended molecular dynamic simulations of a new series of dually acting inhibitors against EGFR and HER2

- New series of anti-EGFR/HER2 agents is ivestigated.
- The new agents can form stable H-bonds with the EGFR/HER2 receptors.
- MD simulations show the ability of binding with additional binding site residues.